What is Lifecore Biomedical, Inc.'s depreciation?

Lifecore Biomedical, Inc. (LFCR) reported depreciation of $2.31M in Q1 2026.

Lifecore Biomedical, Inc. LFCR Depreciation

Depreciation at other companies

Medpace Holdings, Inc.MEDP

——

West Pharmaceutical ServicesWST

——

BioCryst PharmaceuticalsBCRX

——

DanaherDHR

——

Segments

By segment

See full

Reportable Segment$2.31M—

Other financials

Income statement

See full

Revenue$23.2M-36.4%

Gross profit$4.5M-68.1%

Operating income-$4.7M—

Net income-$15.0M-1,206%

EPS (diluted)-$0.43-1,333%

Balance sheet

See full

Cash & equivalents$20.8M+152%

Total debt$156.9M+1,310%

Total equity-$28.4M-2,229%

Total assets$225.5M-5.8%

Cash flow

See full

Operating cash flow$4.7M—

CapEx$1.1M-46.7%

Free cash flow$3.6M—

Valuation

See full

Market cap$196.92M-37.3%

Enterprise value$333.06M+6.3%

P/S1.6×+0.5×

Profitability

See full

Gross margin31.3%-1.4pp

Operating margin-14.5%-2.2pp

Net margin-30%—

FCF margin-36.4%—

Returns & leverage

See full

Return on equity-612.1%—

Debt / equity8.3×-1.5×

Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s depreciation?: Lifecore Biomedical, Inc. (LFCR) reported depreciation of $2.31M in Q1 2026.